All the news

Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented last week at The Liver Meeting 2013, the 64th annual meeting ...

New-onset diabetes is associated with the development of liver cirrhosis and decompensated cirrhosis in people with chronic hepatitis B virus (HBV) infection, according to the results of a study published in the online ...

There is a relatively low incidence of hepatocellular carcinoma (HCC) among people living with HIV who have liver cirrhosis, results of a prospective Spanish study published in the online edition of the ...

Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about  five years, according to a ...

Co-infection with HIV and viral hepatitis is associated with a more aggressive disease course for liver cancer, according to research conducted in London and presented to the recent EASL Monothematic Conference: HIV and ...

The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ...

Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ...

Incidence of liver cancer among people with HIV has increased dramatically over the past decade, Spanish investigators report in the online edition of Clinical Infectious Diseases. All the cases involved individuals with ...

Doctors in Europe and the US have conflicting opinions about the pace of liver fibrosis in HIV-positive men with hepatitis C infection. In a study published in Clinical Infectious Diseases, European investigators ...

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th ...